King & Wood Mallesons advises CR Capital Management on its acquisition of a controlling stake in Dirui Industrial

On 27 November 2020, Shenzhen-based Huade Xinrun Equity Investment Enterprise (limited partnership), a private equity investment vehicle managed by China Resources Capital Management Limited (CR Capital Management), successfully completed the acquisition of a controlling stake of 28% in Dirui Industrial Co., Ltd. (Dirui Industrial, Stock Code: 300396). Headquartered in Changchun, Dirui Industrial Co., Ltd. is listed on the ChiNext market of the Shenzhen Stock Exchange.

Founded in 1992, Dirui Industrial is a global provider of vitro diagnostic products with a focus on seven core business areas, including biochemistry, urinalysis, hematology, gynecology, chemiluminescence immunoassay, blood coagulation analysis and the supply of integrated laboratories. The transaction marks a strategic step in China Resources' ambitions of implementing an integrated, full service supply chain in the medical device sector.

King & Wood Mallesons (KWM) advised CR Capital Management on the investment, including private equity fund formation, registration and the acquisition, securities and financing, as well as the anti-monopoly review.

This deal was led by partners Helena Huang and Yang Ru, with support from partners Molly Su  (Banking & Finance) and Wu Han (Anti-monopoly).